EE79 Cost-Utility Analyses of Glofitamab for the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Two or More Lines of Systemic Therapy in Italy
Abstract
Authors
M. Bellone D. Ghislieri L. Pradelli C. Kokaliaris D. Di Maio